SAT0300 HIGH PROPORTIONS OF DEMENTIA AMONG SLE PATIENTS:
A BIG DATA ANALYSIS Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting wide range of systems including the peripheral and central nervous system 1 . Cognitive impairment leading to dementia is one of the harmful central nervous system manifestations of SLE 2 . Objectives: The aim of this study was to investigate the association of SLE and dementia. Methods: A cross-sectional study was performed utilizing Clalit Health Care database, the largest HMO in Israel with more than 4.4 million enrollees. SLE patients were compared in a 1:5 ratio to age and sex matched controls. Chi-square and t tests were used for univariate analysis, and a logistic regression model was used for multivariate analysis. Results: The study included 4886 SLE patients and 24,430 age and sex frequency matched controls without SLE. The proportion of dementia was higher among SLE patients compared to controls (1.56% and 0.51% respectively; p<0.001). This finding was consistent across all age groups by univariate analysis. In a multivariate logistic regression analysis, SLE was significantly associated with dementia (OR =2.039, 95% CI =1.110-2.039). Conclusions: SLE is significantly associated with dementia. This finding should give rise to search for SLE in patients with an ambiguous cause for dementia, especially those with an early onset cognitive decline. Background: Overexpression of B cell activating factor (BAFF) in salivary glands contributes to the pathogenesis of primary Sjögren's syndrome (pSS) by promoting autoantibody (AAB) production. Treatment of pSS patients with VAY736, an anti-BAFF receptor mAb, appears promising and was associated with a depletion of circulating B cells and a positive therapeutic effect [1] . In addition to the classical anti-SS-A/Ro and anti-SS-B/La, a broader set of AABs may reflect B cell disturbances in pSS and could serve as markers during clinical development of novel pSS therapeutics. Objectives: In this study, we explored novel AABs in pSS patients and healthy controls (HCs) and we tested their associations with the disease, disease activity, and clinical response to VAY736. Methods: Reactivity of AABs to 1,596 antigens was measured in serum samples from 27 pSS patients from a placebo-controlled trial at baseline and posttreatment week 12 and from 50 age and gender-matched HCs. Patients were treated at baseline with a single dose of VAY736 at 10 mg/kg (n=12), 3 mg/kg (n=6), or placebo (n=9). First, to identify AABs associated with pSS, 3 different methods compared AAB levels at baseline between pSS patients and HCs: Wilcoxon rank sum test, significance analysis of microarrays, and comparison of the 90th quantiles between groups. Second, to identify AABs associated with pSS activity, Pearson correlation of AABs with EULAR Sjögren's Syndrome Disease Activity Index, secondary outcomes, and salivary and serum BAFF were tested, using baseline and week 12 levels as well as relative changes. Third, VAY736 treatment-specific changes in AAB levels were investigated using linear mixed-effects models adjusting for dosage, age, and gender effects. Results: Of 1,596 antigens, 36 were statistically different between pSS patients and HCs for at least one of the 3 tests, including the known SS-A/Ro and SS-B/La (significant for all 3 tests) as well as novel antigens. SS-A/Ro and SS-B/La AABs were not associated with disease activity or response to treatment. However, 48 AABs were significantly correlated with pSS activity combining all treatment arms, and 12 AABs had baseline values that correlated with change in pSS activity upon VAY736 treatment (unadjusted p<0.05). Interestingly, 51 serum AABs correlated with BAFF saliva levels (|r|>0.55), but not with BAFF serum levels. The genes encoding novel antigens are involved in apoptotic, anti-viral, metabolic, inflammatory, blood coagulation and B-cell processes, suggesting a possible link to the disease pathology. Finally, there was no reduction in AABs levels in response to VAY736, possibly because the 12 weeks post-treatment analysis was too short to identify large effects. Conclusions: In conclusion, we identified new AABs in pSS patients that have the potential to serve as markers of diagnosis, pSS activity, or as predictors of clinical outcome measures. Further large-scale studies are needed to confirm the value of these markers. -2017-eular.1905 
